Though much is known about diabetic retinopathy (DR), the mechanisms underlying its etiology are still unclear.
Previous studies have reached conflicting results regarding the relationship between obesity and diabetic retinopathy (DR).
An expanded indication for aflibercept injection (Eylea, Regeneron) is now approved by the FDA to treat all stages of diabetic retinopathy (DR).
The study finds that treatment resulted in a significant visual improvement.
“Laser still plays a very important role in the treatment of diabetic macular edema (DME) despite our reliance on anti-vascular endothelial drugs,” said Elias Reichel, MD.
The worldwide incidence of diabetes has been increasing markedly, and by 2014 it had increased to 422 million individuals from 108 million only 34 years previously.
Though anterior uveitis is associated with myriad conditions, a relatively short list of disorders accounts for the vast majority of cases.
With the recent surge in artificial intelligence (AI) and machine learning, ophthalmology is already seeing the benefits.